Neurodevelopmental Outcomes in ZIKV-Exposed Children
Launched by CHILDREN'S NATIONAL RESEARCH INSTITUTE · May 19, 2020
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Zika-virus (ZIKV) infection in pregnancy can result in severe brain damage in 4-12% of cases. Children exposed to ZIKV in utero during the years of 2015-2017 are now in early childhood. Children with severe neurologic injury (Congenital Zika Syndrome; CZS) have a poor developmental outcome, however the developmental outcome of apparently normal infants following in utero ZIKV-exposure is not well known. The incidence of abnormal neurodevelopmental outcome in apparently normal children with in utero ZIKV-exposure is not known.
The investigators will determine if neurodevelopmental assessmen...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Zika-exposed cohort:
- • born to mothers with Zika lab confirmation by PCR, IgM, and/or PRNT, or mother was symptomatic for Zika but infection could not be excluded due to late testing and evaluated at Children's National, Washington, DC (USA) or at BIOMELAB, Barranquilla (Colombia)
- • normal fetal neuroimaging
- • normal birth head circumference
- • normal birth clinical exam
- • no more than mild non-specific postnatal cranial ultrasound or brain MRI findings during infancy (if performed)
- • able to be contacted for follow-up
- Non-ZIKV exposed Controls:
- • healthy
- • no chronic medical conditions
- • no developmental concerns
- • born at term (\>= 37 weeks)
- • birth date prior to March 31, 2016 (Colombian controls)
- Exclusion Criteria:
- Zika-exposed cohort:
- • another diagnosis that would impact neurodevelopment
- • abnormal brain MRI (non-specific mild findings are not an exclusion criteria)
- Non-ZIKV exposed controls:
- • chronic medical condition with in-patient hospitalization since birth
- • under care of a medical specialty provider for a chronic medical condition
- • surgery with general anesthesia since birth (brief anesthesia for ear tubes, tonsillectomy, or other minor pediatric procedure is not an exclusion criteria)
- • history of seizure
- • abnormal vision (children wearing corrective lenses are eligible)
- • abnormal hearing affecting language development
- • developmental concerns expressed by caregiver
- • receiving physical, occupational, speech or developmental therapy
- • receiving special education services in school
- • behavioral or psychological condition
- • birth date March 31, 2016 or later (Colombian controls)
- • preterm birth (≤36 weeks)
- • planned relocation of child within 5 years and likely inability to complete study
About Children's National Research Institute
Children's National Research Institute is a leading pediatric research organization dedicated to advancing the understanding and treatment of childhood diseases. As an integral part of Children's National Hospital, the institute focuses on innovative clinical trials and translational research that aim to improve health outcomes for children. Through collaborations with academic institutions, industry partners, and community organizations, the institute fosters a multidisciplinary approach to research, emphasizing safety, ethical standards, and the integration of cutting-edge technology in pediatric care. With a commitment to addressing the unique health challenges faced by children, Children's National Research Institute strives to translate research findings into effective therapies and interventions that enhance the quality of life for young patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Barranquilla, Atlantico, Colombia
Patients applied
Trial Officials
Sarah B Mulkey, MD, PhD
Principal Investigator
Children's National Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials